Tame Impala’s mysterious video ad for a mock pharmaceutical product called “Rushium,” released June 21, concluding with the detail that “Phase 1 Clinical Trials” would begin in September 2021. Yesterday, on June 22, the artist followed up on that cryptic message with a fall tour announcement that reads like an advertisement for an experimental pharmaceutical drug.
“AionWell® L.T.d, a privately held Australian biopharmaceutical company focused on the development of recombinant stabilization and expansion of cellular space regrowth, has announced today that Kevin Parker, D.B.A. ‘Tame Impala,’ has acquired minority equity interest in AionWell® L.T.d and secured an option to acquire the remaining equity in the company,” the press release reads.
The hypothetical medication that the artist has supposedly become a stakeholder in via payment in Ethereum intends to treat “Acute Time Metagrobolization in Cells (ATMiC),” a cellular condition within the brain’s “Suprachiasmatic nucleus” that apparently affects up to half of the world’s population.
The fall tour dates, which have been rebranded as the “Phase I trials” of Rushium, will kick off on September 4 in Manchester, Tennessee, and come to a close in Dallas, Texas, on November 9. Tame Impala will also make the festival rounds, including stops at Bonnaroo, Life is Beautiful, and Outside Lands.
“Rushium® Has The Ability to Mark and Alter Time Perception,” the announcement concludes.
Tickets for Tame Impala’s tour are on sale now, and tickets for rescheduled shows will be honored, with refunds will be issued for shows no longer happening.
In other music news, here’s everything we know about Tyler, the Creator’s new album.